Yasir B. Al-Wakeel

Insider Reports History

Entity
Individual
Location
Merrimack Pharmaceuticals, Inc., One Kendall Square, Suite B7201, Cambridge, MA
Signature
/s/ Brian Leaf, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Yasir B. Al-Wakeel:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Kronos Bio, Inc. Chief Financial Officer Common Stock 346K $410K $1.18 Jul 6, 2023 Direct
MAXCYTE, INC. Director Common Stock 21.4K $105K $4.90 Jun 11, 2024 Direct
Kronos Bio, Inc. Chief Financial Officer Employee Stock Option (Right to Buy) 208K Feb 15, 2023 Direct
MAXCYTE, INC. Director Stock Option (right to buy) 40.7K Jun 11, 2024 Direct

Insider Reports Filed by Yasir B. Al-Wakeel

Symbol Company Period Transactions Value $ Form Type Date Filed Role
MXCT MAXCYTE, INC. Jun 11, 2024 2 $0 4 Jun 13, 2024 Director
KRON Kronos Bio, Inc. Jul 6, 2023 1 -$16.9K 4 Jul 7, 2023 Chief Financial Officer
MXCT MAXCYTE, INC. Jun 22, 2023 1 $0 4 Jun 23, 2023 Director
MXCT MAXCYTE, INC. Mar 20, 2023 1 $0 4 Mar 21, 2023 Director
KRON Kronos Bio, Inc. Feb 24, 2023 1 -$15.7K 4 Feb 24, 2023 Chief Financial Officer
KRON Kronos Bio, Inc. Feb 15, 2023 2 $0 4 Feb 17, 2023 Chief Financial Officer
KRON Kronos Bio, Inc. Jul 25, 2022 2 $0 4 Jul 27, 2022 Chief Financial Officer
MXCT MAXCYTE, INC. Jun 29, 2022 1 $0 4 Jul 8, 2022 Director
KRON Kronos Bio, Inc. Feb 15, 2022 2 $0 4 Feb 17, 2022 Chief Financial Officer
MXCT MAXCYTE, INC. Aug 9, 2021 1 $0 4 Aug 11, 2021 Director
MXCT MAXCYTE, INC. Jul 29, 2021 0 $0 3 Jul 29, 2021 Director